Truist Securities Reiterates Buy Rating on Axsome Therapeutics (AXSM)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 falls from record high as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Axsome Therapeutics (AXSM) PT Raised to $132 at RBC Capital
November 13, 2024 6:44 AM ESTRBC Capital analyst Leonid Timashev raised the price target on Axsome Therapeutics (NASDAQ: AXSM) to $132.00 (from $131.00) while maintaining a Outperform rating.
The analyst comments "This morning, AXSM reported 3Q24 earnings and we had a chance to catch up with management for additional... More
